Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Make a selection below to explore our full database of 9 results matching: "IR Reid"
ACE Reports
(9 Reports)
ACE Reports
Our AI driven High Impact metric predicts an article's future number of citations by considering the content of the article.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Open Advanced Search
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Exact search includes articles which contain all of the selected filters. Broad search includes articles that have at least one of the selected filters for each category.
Metabolic Disorders
Fracture Prevention with Zoledronate in Older Women with Osteopenia
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Fracture Prevention with Zoledronate in Older Women with Osteopenia
This report has been verified by one or more authors of the original publication.
N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
Osteoarthritis
The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
J Bone Miner Res. 2015 May;30(5):934-44.
The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
J Bone Miner Res. 2015 May;30(5):934-44.
Metabolic Disorders
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial
J Bone Miner Res. 2010 Oct;25(10):2251-5
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial
J Bone Miner Res. 2010 Oct;25(10):2251-5
Metabolic Disorders
The Auckland calcium study: 5-year post-trial follow-up
Osteoporos Int. 2014 Jan;25(1):297-304. doi: 10.1007/s00198-013-2526-z. Epub 2013 Oct 10.
The Auckland calcium study: 5-year post-trial follow-up
This report has been verified by one or more authors of the original publication.
Osteoporos Int. 2014 Jan;25(1):297-304. doi: 10.1007/s00198-013-2526-z. Epub 2013 Oct 10.
General Orthopaedics
Duration of Antiresorptive Effects of Low‐Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009.
Duration of Antiresorptive Effects of Low‐Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
This report has been verified by one or more authors of the original publication.
J Bone Miner Res. 2014 Jan;29(1):166-72. doi: 10.1002/jbmr.2009.
Spine
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial
J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial
This report has been verified by one or more authors of the original publication.
J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292
General Orthopaedics
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494
General Orthopaedics
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial
J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9
Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial
This report has been verified by one or more authors of the original publication.
J Clin Endocrinol Metab. 2012 Jan;97(1):286-92. doi: 10.1210/jc.2011-2081. Epub 2011 Nov 9
General Orthopaedics
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
N Engl J Med. 2009 Aug 20;361(8):756-65. Epub 2009 Aug 11.